PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
Phase 3
Completed
- Conditions
- Hypercholesterolemia, Familial
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2007-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00134511
- Locations
- πΏπ¦
Pfizer Investigational Site, Cape Town, South Africa
Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia
Phase 3
Completed
- Conditions
- Hypercholesterolemia, FamilialHyperlipidemia
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2007-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT00134485
- Locations
Pfizer Investigational Site
A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects
Phase 2
Completed
- Conditions
- Obesity
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2009-08-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 282
- Registration Number
- NCT00134199
- Locations
- πΊπΈ
Pfizer Investigational Site, Tacoma, Washington, United States
Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.
Phase 3
Terminated
- Conditions
- Mixed Hyperlipidemia
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 755
- Registration Number
- NCT00134238
- Locations
- π³π±
Pfizer Investigational Site, Utrecht, Netherlands
A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease
Phase 3
Terminated
- Conditions
- Diabetes MellitusCoronary Disease
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15067
- Registration Number
- NCT00134264
- Locations
- π¬π§
Pfizer Investigational Site, Warwick, United Kingdom
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
- Conditions
- Carcinoma, Renal Cell
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00130897
- Locations
- π»πͺ
Pfizer Investigational Site, Caracas, Estado Miranda, Venezuela
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
Phase 3
Completed
- Conditions
- Lymphoma
- Interventions
- Drug: Investigator's choice
- First Posted Date
- 2005-07-07
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 169
- Registration Number
- NCT00117598
- Locations
- π¬π§
Pfizer Investigational Site, Sutton, Surrey, United Kingdom
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
- First Posted Date
- 2005-06-09
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT00113529
- Locations
- πΊπΈ
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2005-06-09
- Last Posted Date
- 2010-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT00113516
- Locations
- π«π·
Pfizer Investigational Site, Villejuif, France
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
Phase 3
Terminated
- Conditions
- BacteremiaGram-Positive Bacterial Infections
- First Posted Date
- 2005-04-18
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT00108433
- Locations
- πΈπ°
Pfizer Investigational Site, Nitra, Slovakia
Β© Copyright 2025. All Rights Reserved by MedPath